Francois Meyer to head up TxCell

pharmafile | March 9, 2011 | Appointment | Research and Development Francois Meyer, TxCell, appointment, research and development 

French biotech TxCell has appointed François Meyer as chief executive.

He has more than 25 years of pharma and biotech experience, including stints at Ciba-Geigy Pharma, Sandoz Pharma and Aventis Pharma, where he served as head of R&D.

“The appointment of François is a timely and important step in securing the leadership and management structure of the company,” said Marc Lemaire, chairman of the supervisory board of TxCell.

Advertisement

“François’ extensive experience in pharma and biotech will prove invaluable as TxCell pursues its strategy of building a leading company for novel treatments of severe chronic inflammatory diseases.”

Based in Sophia-Antipolis, near Nice, the company’s lead product candidate is a phase IIb treatment for refractory Crohn’s disease. It also has a refractory rheumatoid arthritis candidate currently in phase I/II trials.

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content